Index Ventures

Latest Headlines

Latest Headlines

Backed by J&J and Glaxo, veteran VC group splits from Index, unveils $227M fund

The biotech team at Index Ventures is splitting away to focus exclusively on what they do best: jump-starting new therapeutic programs in Europe.

Novocure files for up to $300M IPO on strength of first-line glioblastoma device

Novocure has filed for an IPO to raise up to $300 million on the strength of a potential FDA approval for its Optune device in combination with chemotherapy for patients with newly diagnosed glioblastoma.

Index Ventures banks €650M for its new tech fund

Index Ventures now has 650 million more euros to invest. The venture group, which has two big teams active on both sides of the Atlantic in life sciences as well as tech, filed documents with the SEC noting that its new Index Ventures Growth III--domiciled in Jersey--is fully sold.

Levicept emerges from Pfizer's R&D ashes with $20M and a new pain drug

Rescued from Pfizer's sweeping R&D cuts, Levicept's lead drug is a protein with promise in chronic pain, and the biotech has raised $15.7 million in venture and grant funding to follow through on its potential.

Top women in biotech 2013

No one ever climbed the industry ladder without getting some help along the way. And for women, including many of the accomplished top performers in this group, that can be especially important....

Egalet scores up to $20M for next-gen pain drug as FDA aims to block abuse

The company develops drug-delivery platforms that offer therapeutic release of pain medicines while making them difficult to abuse. With the new capital, the company plans to advance one of its two lead opioid treatments, Egalet-001, into late-stage clinical development.

Industry Voices: The zero-person biotech company

In recent years, it has become dramatically easier and quicker to create a virtual drug-development company. Today it is even possible to take virtual to its logical extreme: a zero-person biotech company.

Swiss biotech OncoEthix snags $19M round to back leukemia drug study

Switzerland's OncoEthix has raised $19 million in venture cash to back its work on an early-stage cancer treatment, one of a new class of oncology drugs that's been inspiring a range of new clinical trials.

Index Ventures taps Big Pharma-backed fund to hatch anticoagulant upstart

With an experimental therapy that could save "millions of lives," biotech startup XO1 Ltd. said it has raised $11 million in a Series A round of financing from Index Ventures.

Ichorcumab: the blood of the gods?

Index Ventures recently completed an $11 million Series A investment in XO1, an asset-centric company established with the sole objective of developing the monoclonal antibody ichorcumab under license from Cambridge University.